Search - tctmd.com

Displaying 1 - 20 of 231

Sort: Relevancy | Date

News Conference News TCT 2025

At 3 Years, DCBs Still Less Safe Than DES in De Novo CAD: REC-CAGEFREE I

Yael L. Maxwell

November 07, 2025

News Conference News TCT 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

Todd Neale

November 03, 2025

INFINITY-SWEDEHEART: ‘Unlocking’ Stent’s Benefits Seen Over Time

News Conference News TCT 2025

INFINITY-SWEDEHEART: ‘Unlocking’ Device Bests DES Over Time

Michael O'Riordan

October 29, 2025

News Conference News TCT 2025

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

Michael O'Riordan

October 26, 2025

News Opinion Editor's Corner TCT 2025

What’s Going to Be Hot at TCT 2025

Michael O'Riordan

October 09, 2025

News Daily News

Coronary DCB Works Well in Multilayer In-Stent Restenosis: AGENT IDE Subanalysis

L.A. McKeown

August 12, 2025

News Daily News

POPCORN: Hemodialysis Patients Fare Well With Tailored PAD Therapies

L.A. McKeown

July 15, 2025

News Industry News

Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary Vessels

June 12, 2025

News Conference News EuroPCR 2025

Short DAPT All That’s Needed With Contemporary DES: HOST-IDEA at 3 Years

Yael L. Maxwell

June 02, 2025

News Conference News CX Symposium 2025

Paclitaxel or Sirolimus: New PAD Studies Shed Light on Choices

L.A. McKeown

April 23, 2025

News Conference News CRT 2025

AGENT IDE: DCB Performance for In-Stent Restenosis Lasts Out to 2 Years

L.A. McKeown

March 10, 2025

News Daily News

Top Coronary Artery Disease News in 2024

Michael O'Riordan

December 26, 2024

News Conference News ESC 2024

‘Unlocking’ Scaffold Matches DES in Wide Range of PCI Patients, Including ACS

Michael O'Riordan

September 09, 2024

News Daily News

DES Best for In-Stent Restenosis, but DCBs Also Viable

Michael O'Riordan

August 13, 2024

News Conference News EuroPCR 2024

Solid 2-Year Data With ‘Unlocking’ Coronary Stent: BIOADAPTOR RCT

Michael O'Riordan

May 28, 2024

News Conference News SCAI 2024

No Sex-Specific Differences in PAD Therapy Outcomes: REVIVE Analysis

L.A. McKeown

May 10, 2024

News Daily News

As US Rollout Begins for Coronary DCBs, Interventionalists Mull Practice Changes

Todd Neale

May 03, 2024

News Industry News

Concept Medical Announces Enrollment of First Patient in “Magical-ISR” IDE Study in the US

April 19, 2024

News Daily News

Intravascular Imaging Lowers Risk of MACE at 1 Year in Left Main PCI

Michael O'Riordan

March 26, 2024

News Daily News

Agent Coronary DCB Gets FDA Approval for In-Stent Restenosis

L.A. McKeown

March 01, 2024

Advertisement

At 3 Years, DCBs Still Less Safe Than DES in De Novo CAD: REC-CAGEFREE I

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

INFINITY-SWEDEHEART: ‘Unlocking’ Device Bests DES Over Time

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

What’s Going to Be Hot at TCT 2025

Coronary DCB Works Well in Multilayer In-Stent Restenosis: AGENT IDE Subanalysis

POPCORN: Hemodialysis Patients Fare Well With Tailored PAD Therapies

Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary Vessels

Short DAPT All That’s Needed With Contemporary DES: HOST-IDEA at 3 Years

Paclitaxel or Sirolimus: New PAD Studies Shed Light on Choices

AGENT IDE: DCB Performance for In-Stent Restenosis Lasts Out to 2 Years

Top Coronary Artery Disease News in 2024

‘Unlocking’ Scaffold Matches DES in Wide Range of PCI Patients, Including ACS

DES Best for In-Stent Restenosis, but DCBs Also Viable

Solid 2-Year Data With ‘Unlocking’ Coronary Stent: BIOADAPTOR RCT

No Sex-Specific Differences in PAD Therapy Outcomes: REVIVE Analysis

As US Rollout Begins for Coronary DCBs, Interventionalists Mull Practice Changes

Concept Medical Announces Enrollment of First Patient in “Magical-ISR” IDE Study in the US

Intravascular Imaging Lowers Risk of MACE at 1 Year in Left Main PCI

Agent Coronary DCB Gets FDA Approval for In-Stent Restenosis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content